|
Recent Developments |
|
22-FEB-13
Lupin, one of the leading pharmaceutical companies in India, announced today that its subsidiary, Lupin Pharmaceuticals Inc. (collectively, Lupin) has received approval for SUPRAX (ceflixime) for Oral Suspension, 500mg/5ml from the United States Food and Drugs Administration (FDA)
21-FEB-13
Lupin, one of the leading pharmaceutical companies in India has received final approval for its Lorazepam Oral Concentrate USP, 2 mg/mL from the ... More.. |
| Business Profile |
Future Plans |
|
| CEO Talk | | Lupin Ltd is focusing on manufacturing products with high technology barriers through the non-infringing route. D. B. Gupta |
|
|
One To One
|
|
Recent news
|
|
|
| Period ending (months) | 31-Dec-2012(9) | 31-Mar-2012 (12) | 31-Mar-2011 (12) | | Net sales | 54311.20 | 53158.90 | 44262.50 | | Other Income | 516.50 | 34.90 | 29.60 | | Total Income | 54827.70 | 53193.80 | 44292.10 | | Cost of goods sold | 39079.30 | 42229.70 | 35358.60 | | OPBDIT | 15748.40 | 10964.10 | 8933.50 | | PAT | 11274.70 | 8043.70 | 8099.80 | | Gross Block | - | - | - | | Equity capital | 894.80 | 893.30 | 892.40 | | EPS (Rs.) | - | 18.02 | 18.18 | | DPS (Rs.) | - | - | - | | BV (Rs.) | - | - | - | | P/E range (x) | - | 22.45 - 29.56 | 19.14 - 109.19 | | Debt / Equity (x) | - | - | - | | Operating margin (% of OI) | 28.7 | 20.6 | 20.2 | | Net margin (% of OI) | 20.6 | 15.1 | 18.3 |
|
|
Detailed Financials
|
|
|
|
|
Snapshot
